---

High-Yield Clinical Pearls

• Active phase now defined as beginning at 6 cm (not 4 cm) per contemporary evidence — do not diagnose active-phase arrest before 6 cm
• Prolonged latent phase is not an indication for cesarean section
• Maternal obesity significantly slows labor — allow extra time before labeling dystocia

• A single hCG level can never exclude ectopic; serial levels are essential
• hCG discriminatory zone (1,500–2,000 IU/L): if above this and no IUP seen on TVS → high suspicion for ectopic
• 20% of ectopic patients are hemodynamically unstable on presentation → don't delay surgical intervention

• Preeclampsia before 24 weeks is virtually pathognomonic for molar pregnancy
• Always avoid pregnancy for 1 year after complete mole to allow reliable hCG monitoring

• Risk of accreta with placenta previa + 3 prior cesareans = up to 61%
• Attempting manual placental removal → catastrophic hemorrhage
• Planned cesarean hysterectomy with placenta left in situ is the definitive treatment

• MgSO₄ prevents seizures in preeclampsia — it is not an antihypertensive
• First sign of MgSO₄ toxicity: loss of deep tendon reflexes (at ~7–10 mg/dL)
• Respiratory arrest at ~15 mg/dL; cardiac arrest at ~20 mg/dL
• ACE inhibitors and ARBs are absolutely contraindicated in pregnancy
• HELLP can present without severe HTN or proteinuria — always check LFTs and platelets in any pregnant patient with RUQ/epigastric pain

---

Note: Williams Obstetrics is not in this digital library. The information below comes from Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (the most comparable authoritative reference), supplemented by Miller's Anesthesia and Grainger & Allison's Diagnostic Radiology — all of which cover PAS in equivalent or greater depth.

---

Placenta Accreta Spectrum (PAS) — Comprehensive Detail

---

DEFINITION

"Placenta accreta occurs when trophoblast is attached to the myometrium without intervening decidua; that is, invasion beyond the normal boundary established by the Nitabuch fibrinoid layer." — Creasy & Resnik's Maternal-Fetal Medicine

---

THREE DEGREES OF INVASION

Important: PAS is not homogeneous — foci of accreta, increta, and percreta can coexist in the same placenta.

---

WHEN DOES PAS OCCUR? (Incidence & Pathogenesis)

Incidence

• Affects approximately 1 in 300–500 pregnancies
• In developed countries: ~0.17–0.34% of deliveries
• Incidence has risen 10-fold over the past 50 years, driven almost entirely by the rising cesarean delivery rate

Why Does It Happen?

1. Normal uterine surgery (especially cesarean section) creates a scar in the lower uterine segment
2. The scar disrupts the normal endometrial-myometrial interface
3. When the placenta implants over this scar, there is absent or deficient decidua basalis (the normal barrier layer)
4. Without the Nitabuch layer, trophoblasts invade directly into myometrium — or beyond
5. The degree of invasion depends on the depth and extent of the defect

• Abnormal trophoblast biology (excessive invasive tendency)
• Uterine tissue remodeling that exposes vascular myometrium to implantation
• The lower uterine segment has inherently thinner decidua — making it especially vulnerable

---

RISK FACTORS — WHEN IS A WOMAN AT RISK?

Primary Risk Factors

Risk Table (% Risk of Placenta Accreta by Prior Cesareans + Previa Status)

A woman with 3 prior cesareans and a current placenta previa has a >60% chance of PAS.

Additional Risk Factors

• Prior uterine curettage (D&C) — damages the endometrial lining
• Prior myomectomy (especially if uterine cavity entered)
• Endometrial ablation
• Prior uterine rupture or repair
• Pelvic radiation
• In vitro fertilization (IVF)
• Short interpregnancy interval
• Advanced maternal age
• Smoking, increased parity

---

WHEN TO SUSPECT PAS — CLINICAL SCENARIOS

High Suspicion Criteria

1. Placenta previa in a woman with ≥1 prior cesarean — this is the highest-risk scenario
2. Placenta overlying or near a prior uterine scar (even without previa)
3. Prior D&C or uterine surgery + anterior low-lying placenta
4. Unexplained painless vaginal bleeding in a woman with prior cesarean
5. Abnormal ultrasound findings at routine anatomy scan (see Imaging below)

---

DIAGNOSIS

Timing

• Ideally diagnosed prenatally (2nd trimester anatomy scan or earlier in high-risk patients)
• First-trimester diagnosis is possible and accurate, especially in cesarean scar ectopic pregnancy (the precursor lesion)
• All women with clinical risk factors should be referred for obstetric ultrasound at a unit with appropriate expertise

Ultrasound (Primary Diagnostic Tool)

Important caveat: When experts were blinded to clinical status, sensitivity was only 55% — features of accreta can be present in normal placentas.

Key Ultrasound Markers (SMFM Consensus Definitions)

• Accreta: Bridging vessels (71%)
• Increta/Percreta: Placental lacunae + loss of hypoechoic zone + bladder tenting

"The same sonographic features may be identified as early as the first trimester. First-trimester diagnosis is particularly accurate in the setting of cesarean scar ectopic pregnancy." — Creasy & Resnik's Maternal-Fetal Medicine

MRI

• Adjunct to ultrasound — especially useful for:
  • Posterior placentas (ultrasound poorly visualizes posterior wall)
  • Assessing depth of invasion (increta vs. percreta)
  • Bladder or parametrial involvement
  • When ultrasound findings are inconclusive
• MRI features: heterogeneous placental signal, uterine bulge, myometrial thinning (<1 mm) or focal interruption, low T2 signal intensity intraplacental bands, disorganized placental vasculature, loss of uteroplacental zone, bladder tenting/invasion
• Sensitivity ~80%; Specificity ~65% (slightly lower than good-quality ultrasound)
• Combined US + MRI sensitivity: 93%
• No gadolinium contrast required; MRI without gadolinium is safe in pregnancy at any trimester

---

CLINICAL CONSEQUENCES AND COMPLICATIONS

What Happens at Delivery (if Undiagnosed or Unprepared)

Major Complications

---

WHEN SHOULD DELIVERY OCCUR? (Timing of Delivery)

Recommended Timing

"We plan for delivery at 34 to 35 weeks after maternal corticosteroid administration. With this approach, our neonatal outcomes have been favorable. Delivery is performed without amniotic fluid confirmation of fetal lung maturity." — Creasy & Resnik's Maternal-Fetal Medicine

• Risk of massive hemorrhage increases as pregnancy advances and vascularity increases
• Unplanned emergency delivery (in labor or with acute hemorrhage) carries dramatically higher morbidity/mortality than planned elective surgery
• Corticosteroids (betamethasone) administered 48 hours before planned delivery to promote fetal lung maturity at 34–35 weeks

Counseling Before Delivery

1. Planned cesarean hysterectomy as the definitive procedure (placenta left in situ)
2. Expected massive blood loss requiring transfusion
3. Risk of hysterectomy (loss of fertility)
4. Risk of urologic injury (bladder, ureter — especially percreta)
5. Possible ICU admission
6. Neonatal prematurity and NICU stay
7. Option of conservative management (uterus-sparing) and its risks

---

WHEN SHOULD CONSERVATIVE (UTERUS-SPARING) MANAGEMENT BE CONSIDERED?

Appropriate Candidates for Conservative Management

• Small, focal accreta (not extensive)
• Fundal location (after myomectomy or classic cesarean) — away from the bladder
• Posterior placenta (where hysterectomy is technically more complex)
• Strong patient desire to preserve fertility after thorough counseling
• Hemodynamically stable patient

Conservative Management Protocol

1. Fundal hysterotomy (avoiding the placenta) → deliver baby → clamp cord
2. Placenta left completely in situ — do NOT attempt removal
3. Uterus closed
4. Uterine artery embolization (UAE) postoperatively (most common adjunct)
5. Serial hCG monitoring and imaging to track placental resorption
6. Methotrexate is NOT recommended — no proven efficacy + risk of complications (including death reported)

Outcomes of Conservative Management

• 18 of 167 women required primary hysterectomy for intraoperative bleeding
• Another 18 required delayed hysterectomy
• Severe morbidity in 10 women; 1 death from methotrexate complications
• Of 15 subsequent pregnancies: 6 first-trimester losses, 4 preterm births, 2 recurrent accretas
• Risk may be higher in true histologically confirmed accretas (many conservative cases lacked histologic confirmation)

"Conservative management should be undertaken with extreme caution and appropriate counseling regarding risks." — Creasy & Resnik's Maternal-Fetal Medicine

---

DEFINITIVE MANAGEMENT — CESAREAN HYSTERECTOMY

Where: Center of Excellence (Level III or IV Maternal Care Facility)

"Outcomes are improved and the chances of complications diminished when accretas are managed at regional referral centers or 'centers of excellence.'" — Creasy & Resnik's Maternal-Fetal Medicine

Multidisciplinary Team Required

• Maternal-Fetal Medicine (MFM) specialist
• Experienced pelvic/gynecologic oncology surgeon (capable of wide resection)
• Urology (if bladder involvement expected)
• Interventional Radiology (IR)
• Anesthesiology (obstetric anesthesia team)
• Blood bank / Transfusion medicine (massive transfusion protocol)
• Neonatology
• ICU team

Surgical Steps

1. Fundal hysterotomy (classical/vertical incision avoiding the placenta) → deliver baby
2. Cord clamped immediately
3. Placenta left completely in situ (no attempt to remove it)
4. Proceed to total abdominal hysterectomy with placenta inside
5. Wide resection of lower uterine segment and parametrial tissues as needed
6. Bladder dissection if percreta with bladder involvement

Blood Loss Reduction Strategies

• Cell salvage (autotransfusion) intraoperatively
• Massive transfusion protocol (packed RBCs + FFP + platelets in 1:1:1 ratio)
• Balloon occlusion of internal iliac arteries, common iliac arteries, or aorta:
  • Preoperative IR placement of balloon-tipped catheters retrograde
  • Inflated just before uterine incision to reduce pelvic blood flow
  • Reduces blood loss during resection of lower uterine segment
  • Efficacy varies; preferred: common iliac balloons (cover most extrauterine supply)
  • Caution: uterine artery balloon inflation before delivery can cause fetal anoxia
• Selective embolization of uterine vessels near time of delivery

---

SUMMARY: KEY CLINICAL POINTS

---

---

Source note: Williams Obstetrics is not available in this digital library. All content below is drawn from Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (the authoritative equivalent) and corroborated by Rosen's Emergency Medicine and Textbook of Family Medicine, 9th ed.

---

Placental Abruption (Abruptio Placentae) — Complete Detailed Reference

---

DEFINITION

"Abruptio placentae is the premature separation of a normally sited placenta before birth, after 20 weeks' gestation. It is a particularly hazardous condition associated with significant maternal and fetal morbidity and mortality." — Creasy & Resnik's Maternal-Fetal Medicine

---

INCIDENCE AND EPIDEMIOLOGY

---

PATHOGENESIS — HOW DOES IT HAPPEN?

The Core Mechanism

1. Hemorrhage occurs between the decidua basalis and the placenta (retroplacental hematoma)
2. The hematoma dissects the decidua apart → progressively separates the placenta from the uterine wall
3. The separated area loses its function — no gas exchange, no fetal nutrition in that zone
4. Process may be self-limited (minor separation, small hematoma) or progressive (expanding hematoma → greater separation → fetal compromise)

How Bleeding Presents

• External (revealed) bleeding: dissection reaches the placental edge, tracks between the fetal membranes and uterine wall, exits through the cervix → visible vaginal bleeding
• Concealed (occult) bleeding: blood is trapped behind the placenta — no external bleeding despite massive internal hemorrhage
• Mixed: combination of both (most common)

Underlying Vascular Events

• Primary cause: vasospasm of abnormal maternal arterioles in the decidua
• Some cases: venous hemorrhage into areas of necrotic decidua secondary to thrombosis
• Evidence of preexisting placental pathology: poor trophoblastic invasion, abnormal uterine artery Doppler flow, inadequate spiral artery remodeling — all linking abruption to preeclampsia and IUGR as a common placental disorder
• Marker: women destined to have abruption have low levels of pregnancy-associated plasma protein A (PAPP-A) — may be detected at first-trimester screening

Couvelaire Uterus

• Retroplacental blood penetrates the full thickness of the myometrium into the peritoneal cavity
• Myometrium becomes infiltrated with blood → purple, bruised, board-like uterus (Couvelaire uterus / uteroplacental apoplexy)
• Myometrium becomes weakened and atonic → risk of uterine rupture (rare) and postpartum hemorrhage
• In near-complete or complete abruption with Couvelaire uterus → fetal death is inevitable without immediate cesarean delivery

DIC Cascade

1. Massive hemorrhage activates the coagulation cascade
2. Ongoing bleeding → consumption of clotting factors → DIC
3. Maternal hypovolemia + poor tissue perfusion → aggravates DIC
4. Downward spiral: hemorrhage → DIC → more bleeding → hemorrhagic shock

---

RISK FACTORS

Strongest Risk Factors

Additional Risk Factors

"The most important risk factor for abruption is a history of abruption in a prior pregnancy." — Creasy & Resnik's Maternal-Fetal Medicine

"40–50% of women with abruptio placentae have underlying hypertension." — Textbook of Family Medicine 9e

---

CLINICAL CLASSIFICATION — SEVERITY SPECTRUM

Grade 0 — Subclinical / Asymptomatic

• No symptoms
• Retroplacental clot identified only on placental examination after delivery
• No maternal or fetal compromise

Grade 1 — Mild Abruption

• Slight vaginal bleeding (may be absent — concealed)
• Mild uterine tenderness, little or no irritability
• No fetal distress
• Normal maternal vital signs
• Normal coagulation studies
• No maternal hemodynamic instability

Grade 2 — Moderate Abruption

• Moderate vaginal bleeding (or significant concealed hemorrhage)
• Increased uterine irritability ± tetanic contractions
• Fetal distress present (FHR abnormalities)
• Maternal tachycardia
• Declining fibrinogen levels
• No overt maternal shock

Grade 3 — Severe Abruption (~15% of cases)

• Massive bleeding (overt or concealed) → maternal hypotension/shock
• Tetanically contracted, extremely painful, board-like uterus
• Fetal death
• Fibrinogen <150 mg/dL (overt DIC)
• Maternal coagulopathy
• Risk of Couvelaire uterus, renal cortical necrosis, pituitary necrosis (Sheehan syndrome)

"Massive, concealed abruption often manifests with severe pain, a hard tonically contracting uterus, and a dead fetus; such a picture may occur in association with severe preeclampsia or recent use of cocaine." — Creasy & Resnik's Maternal-Fetal Medicine

---

CLINICAL FEATURES — SIGNS AND SYMPTOMS

Special Presentations

• Posterior placenta: severe back pain may be the only symptom; worsened by anterior abdominal palpation pushing fetus into placenta
• Idiopathic preterm labor: abruption should always be considered when no other cause for preterm labor is found
• Traumatic abruption: may have no symptoms for up to 24 hours after trauma (MVA, fall, IPV)
• Chronic abruption-oligohydramnios sequence (CAOS): recurrent bleeding from chronic retroplacental bleeding → oligohydramnios develops without evidence of ruptured membranes; all patients deliver preterm (average 28 weeks)

---

DIAGNOSIS

Primary: Clinical Diagnosis

"Abruptio placentae is a clinical diagnosis. Painful vaginal bleeding in the third trimester is the hallmark." — Textbook of Family Medicine 9e

Ultrasound

• Primary role: exclude placenta previa (not confirm abruption)
• Sensitivity for abruption: low — at least 50% of abruptions produce NO findings on ultrasound
• Fresh blood is isoechoic or hyperechoic relative to the placenta → invisible in acute phase
• As hematoma ages (over days): becomes hypoechoic → sonolucent (typically by 2 weeks)
• "Jello sign": intrauterine clot jiggles when bounced by the transducer
• Absence of US findings never excludes abruption

Cardiotocography (CTG / Electronic Fetal Monitoring)

• Most sensitive test for detecting fetal compromise
• 100% negative predictive value for adverse outcomes when monitoring is reassuring
• FHR abnormalities: variable decelerations, late decelerations, poor variability, prolonged bradycardia, sinusoidal pattern → reflect fetal asphyxia
• Uterine contractions may be present that are not clinically felt — especially post-trauma
• Should begin immediately and be continuous

Laboratory Studies — Complete Panel

"Fibrin degradation products are almost always elevated — the most sensitive lab test." "The wall clot test: take blood in a tube — if it doesn't clot in 6 minutes or the clot lyses within 30 minutes → severely abnormal coagulation."

---

FETAL AND NEONATAL CONSEQUENCES

"20% of all fetal deaths from abruption occur after presentation to the hospital, and 30% of those deaths occur within 2 hours after admission." — Creasy & Resnik's Maternal-Fetal Medicine

---

MATERNAL COMPLICATIONS

---

DIFFERENTIAL DIAGNOSIS

"All patients with painless second-trimester vaginal bleeding should be assumed to have placenta previa until proven otherwise by ultrasound before considering abruption."

---

MANAGEMENT

Guiding Principle

"The key to optimizing maternal and fetal outcomes in abruptio placentae is the individualization of care. Precise management depends on the extent of maternal and fetal compromise and the gestational age." — Creasy & Resnik's Maternal-Fetal Medicine

Immediate Stabilization — All Cases

1. Two large-bore IV lines (large-gauge; central line or arterial line if hemodynamically unstable)
2. Continuous electronic fetal monitoring — start immediately, maintain continuously
3. Indwelling urinary catheter — to monitor urine output closely (target >30 mL/hr)
4. Supplemental oxygen
5. Left lateral tilt (reduce aortocaval compression)
6. Obstetric team + anesthesia notified immediately

Laboratory Workup

• CBC with platelets
• Type and crossmatch
• PT, PTT, fibrinogen, thrombin time, FDP/D-dimer
• BMP (renal function)
• Wall clot test (bedside: blood in red-top tube → should clot within 6 min)
• Kleihauer-Betke (only for Rh dosing, not diagnosis)
• Baseline fibrinogen is the most important serial monitor

Imaging

• Ultrasound: exclude placenta previa; may or may not show retroplacental clot
• CTG: begin immediately; most sensitive indicator of fetal status

Decision Tree Based on Clinical Scenario

---

Scenario 1: Severe Abruption (Grade 3) — Any Gestation

• Usually by emergency cesarean section — unless patient is in advanced active labor with imminent vaginal delivery
• Massive transfusion protocol:
  • Packed RBCs
  • Fresh frozen plasma (FFP) — replace clotting factors
  • Platelets (if <50,000 or actively bleeding)
  • Cryoprecipitate (if fibrinogen <200 mg/dL)
  • Fibrinogen concentrate if available
  • Target fibrinogen >200 mg/dL to reduce bleeding
• Treat DIC aggressively
• If Couvelaire uterus → at risk for uterine atony postoperatively → have oxytocin, ergometrine, carboprost ready
• If Rh-negative → administer Rh immune globulin 300 µg within 72 hours

---

Scenario 2: Moderate/Severe Abruption with Fetal Compromise — Any Gestation

• Do not delay for steroid administration
• Same resuscitation as above

---

Scenario 3: Abruption ≥34 Weeks — Stable Mother, No Severe Fetal Distress

"If the event occurs after 34 weeks' gestation, delivery should not be delayed, because the risks of conservative management outweigh any considerations of prematurity." — Creasy & Resnik's Maternal-Fetal Medicine

• Route: vaginal if labor progressing and fetal status allows; cesarean if indicated
• Amniotomy often performed — confirms bleeding is not from previa, may hasten labor, allows IUPC placement

---

Scenario 4: Abruption 20–34 Weeks — Stable Mother AND Fetus

• Hospital admission mandatory
• Continuous CTG monitoring
• Serial laboratory work (fibrinogen q4–6h)
• Betamethasone 12 mg IM × 2 doses 24 hours apart for fetal lung maturity
• Serial growth ultrasounds + Doppler studies
• Tocolysis: use with extreme caution (magnesium sulfate if needed for lung maturity/neuroprotection; avoid beta-agonists which can mask tachycardia of blood loss)
• Patient counseled re: risk of evolving abruption — may need emergency delivery at any time

"The patient should be monitored closely because she continues to be at risk of an evolving process."

---

Scenario 5: Post-Trauma (MVA, Fall, IPV) — Any Gestation

• Asymptomatic after trauma: CTG monitoring for minimum 6 hours; if reassuring → can discharge
• Bleeding or contractions after trauma: monitor for at least 24 hours; abruption may be delayed in presentation
• Kleihauer-Betke for Rh dosing
• Serial fibrinogen and coagulation studies

---

Coagulation Management Table

---

RECURRENCE AND COUNSELING

Counseling Points for Future Pregnancies

• Risk of recurrence is substantial — must be disclosed
• Modifiable risk factors should be addressed before conception:
  • Stop smoking (even stopping before pregnancy carries some residual risk)
  • Avoid cocaine and other vasoactive substances
  • Optimize blood pressure control (preconception visit for hypertensive patients)
  • Treat thrombophilias (e.g., aspirin for APS)
• Low-dose aspirin (81 mg/day from 12 weeks) — reduces risk in women with prior preeclampsia/abruption through antiplatelet and anti-inflammatory effects
• First-trimester PAPP-A screening and uterine artery Doppler may identify high-risk women earlier
• Early ultrasound surveillance for IUGR, abnormal Doppler
• Antenatal fetal surveillance from 28–32 weeks in women with prior abruption

---

SUMMARY AT A GLANCE

---

---

Source note: Williams Obstetrics is not in this digital library. Content below is drawn from Creasy & Resnik's Maternal-Fetal Medicine: Principles and Practice (primary), Rosen's Emergency Medicine, Morgan & Mikhail's Clinical Anesthesiology, Textbook of Family Medicine 9e, and Grainger & Allison's Diagnostic Radiology — all authoritative peer-level references.

---

Placenta Previa — Complete Detailed Reference

---

DEFINITION

Modern (Current) Terminology

"The previous categories of placenta previa — complete, partial, marginal — are no longer recommended." — Creasy & Resnik's Maternal-Fetal Medicine

---

INCIDENCE

---

PATHOGENESIS — WHY DOES IT HAPPEN?

Primary Mechanism

• Prior endometrial damage (from curettage, surgery, infection, scarring) → less favorable endometrium in the upper uterus → placenta implants lower where vascularization is accessible
• The LUS has relative endometrial deficiency → abnormally implanted placenta

• The placenta does not physically migrate — it grows preferentially toward better blood supply at the fundus
• Distal portions near the lower segment with poorer blood supply regress and atrophy over time → placenta "moves away" from os
• Simultaneously, differential growth of the LUS pulls the lower placental edge further from the os as pregnancy advances

"The placenta clearly does not move; rather it is likely that the placenta grows toward the better blood supply at the fundus (trophotropism), leaving the distal portions closer to the relatively poor blood supply of the lower segment to regress and atrophy." — Creasy & Resnik's Maternal-Fetal Medicine

Why Does Bleeding Occur?

• As the LUS develops in late pregnancy, the cervix effaces and the lower segment elongates
• Marginal placental sinusoids are torn as the LUS stretches
• Prelabor Braxton-Hicks contractions, cervical dilation, intercourse, or vaginal examination can all provoke bleeding
• Once labor begins, cervical dilation forces progressive placental separation → significant hemorrhage

---

RISK FACTORS

"There is a clear association between placental implantation in the lower uterine segment and prior endometrial damage and uterine scarring from curettage, surgical insult, prior placenta previa, or multiple prior pregnancies." — Creasy & Resnik's Maternal-Fetal Medicine

---

CLINICAL FEATURES

Classic Presentation

"The classic history for placenta previa is that of painless third-trimester bleeding." — Creasy & Resnik's Maternal-Fetal Medicine

Special Presentations

• Complete (central) previa: earlier, more severe bleeding episodes; highest hemorrhage risk
• Posterior previa: may be more difficult to diagnose on transabdominal US; may present with back pain
• Provoked bleeding: after intercourse, speculum examination, or digital vaginal examination

What is NOT Present (distinguishes from Abruption)

• No uterine tenderness
• No hypertonic uterus
• No fetal distress (initially)
• No DIC (unless massive hemorrhage occurs)

---

DIAGNOSIS

Rule #1 — Critical Safety Point

⚠️ DO NOT perform digital vaginal examination until placenta previa has been excluded by ultrasound. Digital examination can precipitate catastrophic, life-threatening hemorrhage.

Ultrasound — Diagnostic Method of Choice

• First-line screening tool
• Accuracy 93–98%
• False positives from: full bladder (pushes anterior uterine wall down, mimicking previa), focal uterine contractions
• Inferior to TVS for definitive placental localization
• Posterior placentas difficult to visualize accurately

• More accurate than TAS; can precisely measure os-to-placental-edge distance
• Proven safe — concerns about provoking bleeding are unfounded
• Technique: probe inserted under continuous US visualization; avoid placing probe into a dilated cervix; do not advance beyond the lower vagina
• Bladder must be EMPTY — full bladder causes false-positive diagnosis by pushing uterine walls together
• Translabial (transperineal) scanning is an alternative if TVS unavailable

"Double-Setup" Examination

• Significant third-trimester bleeding
• Ultrasound unavailable
• Diagnosis not established

1. Patient taken to operating room
2. Full preparation for immediate cesarean delivery
3. Vaginal exam starting at vaginal fornices (not directly at cervix)
4. If previa detected → proceed immediately to cesarean
5. If no previa → continue evaluating for other bleeding causes

---

PLACENTAL MIGRATION — RESOLUTION OVER TIME

Factors That Predict Persistence to Term

• Degree of overlap: the more the placenta overlies the os, the more likely it is to persist
• Thickness of placental edge: thick posterior edge → less likely to migrate
• Complete (central) previa — much more likely to persist than marginal/low-lying
• Earlier in pregnancy the diagnosis is made → less likely to persist

Recommended Follow-up Protocol (Creasy & Resnik)

1. Follow-up US at 32 weeks — re-evaluate placental position
2. If significant change is seen → final US at 36 weeks before deciding delivery route
3. If no change (still covering os) → plan cesarean delivery

---

COMPLICATIONS

Maternal

Fetal/Neonatal

---

ASSOCIATED CONDITIONS

Vasa Previa — Critical Emergency

• Fetal blood vessels (unsupported by Wharton's jelly) traverse the fetal membranes and overlie or cross the internal cervical os
• Almost always associated with velamentous cord insertion (cord inserts into membranes rather than placenta) or succenturiate (accessory) lobe
• If undiagnosed and membranes rupture → fetal vessels torn → fetal exsanguination in minutes
• Fetal mortality: 33–100% if undiagnosed before labor; 97% survival with antenatal diagnosis and planned cesarean
• Can mimic placenta previa on presentation (vaginal bleeding)
• Diagnosed by: color Doppler TVS showing vessels overlying os; vessels do not change position with maternal repositioning (unlike umbilical cord loop)
• Management: planned cesarean at ~36 weeks; consider hospitalization from 28–32 weeks

Placenta Accreta Spectrum (PAS)

• PAS is the most feared complication of placenta previa
• With complete previa + prior cesarean: risk of PAS up to 61% with ≥3 prior C/S
• Any woman with previa overlying a cesarean scar must be evaluated for PAS

---

MANAGEMENT

Guiding Principle

1. Gestational age
2. Amount of bleeding
3. Maternal hemodynamic stability
4. Fetal condition
5. Whether the placenta has resolved or persists

---

Step 1: Immediate Assessment (ALL Patients with Suspected Previa)

• Do NOT perform digital vaginal exam
• Admit to labor and delivery
• Continuous electronic fetal monitoring
• Two large-bore IV lines
• Maternal vital signs — frequent monitoring
• Blood: CBC, type and crossmatch, coagulation panel (PT/PTT, fibrinogen, FDP), hematocrit
• Obstetric Hemorrhage Protocol:
  • Type & cross 4 units of PRBCs
  • Lab stays 4 units ahead of blood use
  • 2 units FFP thawed and available
  • 1 ten-pack of platelets available
  • Wall clot test: tube of blood should clot within 6 minutes
• Rh immune globulin 300 µg if Rh-negative and not yet given at 28 weeks
• Ultrasound to confirm placenta previa and assess fetal well-being

---

Step 2: Management Based on Clinical Scenario

Scenario A: Massive/Uncontrolled Hemorrhage — Any Gestation

• Under general anesthesia if hemodynamically unstable
• Two large-bore IVs, aggressive fluid resuscitation
• Activate massive transfusion protocol
• Deliver regardless of gestational age

Scenario B: Confirmed Previa, Stable, ≥36 Weeks

"If the diagnosis is clearly placenta previa and the patient is at or beyond 36 weeks' gestation, delivery is appropriate." — Creasy & Resnik's Maternal-Fetal Medicine

• Amniocentesis for lung maturity confirmation not needed
• Plan delivery at or just after 36 weeks — risk of sudden excessive hemorrhage outweighs any fetal benefit of waiting longer

Scenario C: Confirmed Previa, Stable, 34–36 Weeks

• Betamethasone for fetal lung maturity (if <34 weeks or borderline)
• Hospital admission until at least 48 hours bleed-free
• Home management may then be considered if:
  • Asymptomatic (no active bleeding, no pain)
  • Can maintain limited activity at home
  • Adequate support system
  • Lives close to hospital (immediate access if bleeding recurs)
  • A second significant bleed → readmission until delivery
• Expectant management prolongs pregnancy by average 4 weeks after initial bleed
• Avoid intercourse, pelvic rest, reduce activity

Scenario D: Confirmed Previa, Stable, <34 Weeks

• Betamethasone 12 mg IM × 2 doses (q24h) for fetal lung maturity
• Tocolysis — controversial but both β-mimetics and MgSO₄ have been used with apparent prolongation of pregnancy without adverse effects
• Cervical cerclage — evaluated in small studies; no clear benefit; not recommended
• Bed rest, avoid intercourse
• Close fetal and maternal monitoring

Scenario E: Low-Lying Placenta (Edge 1–20 mm from Os)

"An asymptomatic woman whose placenta lies more than 2 cm from the cervical os can be allowed to labor safely."

• If placental edge >20 mm from os at 36 weeks → safe for vaginal delivery
• If placental edge ≤20 mm or covering os → cesarean delivery required
• Even low-lying placenta (not covering os) → increased risk of postpartum hemorrhage from LUS atony

---

Step 3: Cesarean Delivery Technique

"Cesarean delivery for placenta previa should be performed by the most experienced team available because of the substantial risk of intraoperative hemorrhage." — Creasy & Resnik's Maternal-Fetal Medicine

• In most cases: lower uterine segment transverse incision is appropriate
• If anterior placenta overlies the intended incision:
  • Immediately clamp the umbilical cord upon entry to prevent blood loss from placental disruption
  • Vertical (classical) incision may be preferable — especially with prematurity or transverse lie
• Avoid cutting through the placenta if possible — go around it

1. Oxytocin (high-dose IV)
2. Methyergonovine (Methergine) — if not hypertensive
3. Carboprost tromethamine (Hemabate) — 15-methyl PGF₂α
4. B-Lynch compression suture (brace suture of uterus)
5. Local suturing of the placental bed
6. Bakri balloon — intrauterine tamponade balloon for PPH control after C/S
7. Hysterectomy — last resort for refractory hemorrhage

Anesthesia

• Spinal or epidural (regional) preferred in stable patients
• General anesthesia required for: hemodynamic instability, active massive hemorrhage, need for emergency delivery

---

FOLLOW-UP ULTRASOUND SCHEDULE

---

ABRUPTION vs. PREVIA — Comparison

---

HIGH-YIELD CLINICAL PEARLS

1. Any painless vaginal bleeding after 20 weeks = placenta previa until proven otherwise by ultrasound
2. Never perform digital exam until placenta previa excluded — can cause catastrophic hemorrhage
3. TVS is safe and more accurate than TAS — do not avoid it out of fear of provoking bleeding; monitor probe insertion on screen
4. Empty the bladder before TVS — full bladder gives false-positive previa
5. 90% of previas found in 2nd trimester resolve — do not over-counsel early
6. Follow-up US at 32 weeks then 36 weeks before delivery decision
7. Deliver at 36 weeks for confirmed previa — risk of sudden hemorrhage outweighs prematurity risk after this gestation
8. Complete previa with anterior location + prior cesarean = evaluate aggressively for PAS
9. The LUS does not contract well after placental delivery → anticipate PPH; have uterotonic agents ready
10. A low-lying placenta (even not covering os) still increases PPH risk from LUS atony

---

---

Source note: Williams Obstetrics is not available in this library. Content is drawn from Creasy & Resnik's Maternal-Fetal Medicine, Tintinalli's Emergency Medicine, Rosen's Emergency Medicine, Roberts & Hedges' Clinical Procedures, and Textbook of Family Medicine 9e — all authoritative peer-level references.

---

Ectopic Pregnancy — Complete Detailed Reference

---

DEFINITION

"Ectopic pregnancy occurs when a conceptus implants outside of the uterine cavity; ruptured ectopic pregnancies are a leading cause of maternal death in the first trimester of pregnancy." — Tintinalli's Emergency Medicine

---

INCIDENCE AND EPIDEMIOLOGY

---

ANATOMIC LOCATIONS

"The vast majority of ectopic pregnancies implant in the ampullary portion of the fallopian tube. The underlying cause is most often damage to the tubal mucosa from previous infection, preventing transport of the ovum to the uterus." — Tintinalli's Emergency Medicine

---

PATHOPHYSIOLOGY

Normal Fertilization and Implantation

• Fertilization occurs in the ampullary segment of the fallopian tube, approximately 8–9 days after ovulation
• The zygote normally travels along the tube and implants in the endometrium
• Normal peristalsis + ciliary action transport the embryo toward the uterus in 3–4 days

What Goes Wrong in Ectopic Pregnancy

• Tubal scarring from prior infection (PID) → damaged mucosal cilia, impaired peristalsis, tubal stricture
• Fertilized ovum stalls in the tube → implants in tubal wall
• Tubal surgery → disrupts normal tubal architecture

• Defects in the ovum → premature implantation before it reaches the uterus
• Elevated estradiol or progesterone → inhibits tubal migration

• Inhospitable endometrium → embryo more likely to implant ectopically

What Happens After Tubal Implantation

1. Trophoblasts penetrate the muscular tubal wall — blood seeps into tubal tissue
2. Intermittent distention of the tube with blood → intermittent pain
3. Blood leaks from fimbriated end into peritoneal cavity (→ hemoperitoneum) or through the tubal wall
4. The aborting ectopic may:
   • Tubal abortion: expelled out the fimbrial end into the peritoneal cavity (usually ~6 weeks)
   • Tubal rupture: tube tears, causing sudden massive hemorrhage (usually 6–10 weeks for ampullary; earlier for isthmic; later for interstitial)
5. Death from maternal exsanguination after rupture — can occur within minutes

---

RISK FACTORS

Important: Risk factors absent in almost half of patients — ectopic pregnancy must be considered in any woman of reproductive age with pain and/or vaginal bleeding regardless of risk factor profile.

"Pregnancy in a patient with prior tubal surgery for sterilization is assumed to be an ectopic pregnancy until proven otherwise." — Tintinalli's Emergency Medicine

---

CLINICAL FEATURES

Classic Triad

1. Amenorrhea (delayed menses)
2. Abdominal/pelvic pain
3. Vaginal bleeding (usually light)

Warning: This classic triad is present in only a minority of cases. The presentation is highly variable.

Symptoms

Physical Examination

"Blood in the peritoneal cavity does not consistently correlate with peritoneal irritation, blood pressure, or pulse rate. Bradycardia in the presence of significant intraperitoneal bleeding from a ruptured ectopic pregnancy is not unusual." — Roberts & Hedges' Clinical Procedures

"Vital signs may be normal despite significant hemoperitoneum." — Tintinalli's Emergency Medicine

---

DIAGNOSTIC APPROACH

The Core Principle

"Because the history and physical examination are insensitive and nonspecific, pelvic ultrasonography and serum hCG are essential to locate the pregnancy in any patient who has abdominal pain or vaginal bleeding and a positive pregnancy test." — Rosen's Emergency Medicine

---

Step 1: Urine or Serum Pregnancy Test

• First step in any woman of reproductive age with pain or bleeding
• Qualitative urine hCG: highly sensitive; if positive → pursue ultrasound and quantitative hCG
• A single hCG level cannot exclude ectopic pregnancy — even very low levels (<500 mIU/mL) have been associated with ruptured ectopics requiring surgery

---

Step 2: Transvaginal Ultrasound (TVS) — Primary Diagnostic Tool

• TVS: IUP should be visible at hCG ≥1,500–2,000 mIU/mL (institution-dependent)
• TAS: IUP should be visible at hCG ≥6,000 mIU/mL
• If hCG above discriminatory zone and no IUP seen on TVS → ectopic pregnancy must be strongly suspected
• However: ectopic pregnancy can occur and rupture at any level of hCG, including <500 mIU/mL

• Gestational sac: ~4.5 weeks by TVS
• Yolk sac: ~5.5 weeks by TVS
• Fetal pole: ~6.0 weeks by TVS (TAS: ~1 week later than TVS)

• Among patients with indeterminate US: 53% → embryonic demise; 15% → ectopic; only 29% → normal IUP

Critical Point: An IUP on ultrasound does not rule out ectopic in ART patients — heterotopic pregnancy must be considered. For spontaneous conceptions, demonstrating an IUP provides high confidence against ectopic.

---

Step 3: Serial Quantitative β-hCG Levels

"~15% of normal IUPs have a minimal rise in hCG, requiring a third serial test."

"Ruptured ectopic pregnancies requiring surgery have been reported with very low or absent levels of hCG."

---

Step 4: Serum Progesterone

• Not a standard ED tool but useful adjunct in stable patients with indeterminate US + low hCG
• A value <5 ng/mL → can proceed to D&C to look for chorionic villi

---

Step 5: Other Diagnostic Modalities

• Identifies chorionic villi in endometrial samples → confirms failing IUP and excludes ectopic (in ~70% of cases even with empty uterus on US)
• Can identify villi in 50% of women with empty uterus on US
• Used when: non-rising hCG, indeterminate US, stable patient
• If no villi found → strong suspicion for ectopic → proceed to medical or surgical management

• Aspiration of cul-de-sac through posterior vaginal fornix
• Non-clotting blood = hemoperitoneum = strongly suggestive of ectopic
• Replaced by TVS; poor sensitivity; false positives from vascular structures; rarely used now

• Gold standard for diagnosis — most accurate
• Appropriate for: unstable patients, peritoneal signs, nondiagnostic US, need for simultaneous treatment
• Can be both diagnostic and therapeutic in the same setting

• High sensitivity and specificity
• Theoretical interest only in acute setting — too slow, costly, limited availability

---

CLASSIFICATION BY HEMODYNAMIC STATUS

Unstable (~20% of cases)

• Hypovolemia, shock, significant hemoperitoneum (free fluid in Morrison's pouch), open cervical os, peritoneal signs
• → Emergency surgery immediately — no time for further diagnostic workup

Stable (~80% of cases)

• Goal: locate the pregnancy and determine viability before deciding management
• Management based on US + hCG pattern + clinical context

---

MANAGEMENT

A. Unstable Patient — Surgical Emergency

1. Two large-bore IV lines → aggressive crystalloid + blood product resuscitation
2. Type and crossmatch, CBC, coagulation studies
3. Emergency laparoscopy (preferred) or laparotomy if hemodynamically crashing
4. Salpingectomy (removal of tube containing ectopic) in most rupture cases
5. Salpingostomy (linear incision, ectopic removed, tube preserved) if tube-sparing desired — but higher risk of persistent ectopic (~5–20%); requires serial hCG follow-up
6. Rh immune globulin 50–300 µg IM if Rh-negative (within 72 hours)

B. Stable Patient — Medical Management with Methotrexate (MTX)

Criteria for MTX Eligibility (all must be met):

• Hemodynamically stable
• Unruptured ectopic (confirmed on US)
• Able to comply with follow-up (serial hCG monitoring weekly)
• No contraindications

Absolute Contraindications to MTX:

MTX Regimens:

• 50 mg/m² IM
• Check hCG on day 4 and day 7 post-injection
• Expected: hCG should decrease ≥15% between days 4 and 7
• If <15% decline → repeat dose or proceed to surgery
• Success rate: 88.1% overall; drops to 86% if hCG >5,000 mIU/mL
• Failure rate ~14.3% when hCG >5,000 mIU/mL vs. only 3.7% when <5,000 mIU/mL

• MTX + leucovorin (folinic acid) on alternating days
• Success rate 92.7% — higher than single dose

Common Side Effects of MTX:

• Abdominal pain in up to 75% (3–7 days after treatment) — "separation pain" from tubal abortion / hematoma; usually self-limited; treat with NSAIDs
• Flatulence
• Stomatitis (mouth sores)
• Nausea, vomiting
• Bone marrow suppression (rare at single-dose regimen)
• Photosensitivity — avoid sun exposure during treatment

Distinguishing "Separation Pain" vs. Rupture:

• Both occur 3–7 days after MTX
• Separation pain: mild-moderate, self-limited
• Rupture: severe, with hemodynamic instability, free fluid on US, falling hematocrit
• Evaluation: CBC + abdominal US to rule out hemoperitoneum
• If moderate/severe pain + free fluid + rebound → proceed to surgery

Patient Instructions After MTX Discharge:

• Return immediately for: vaginal bleeding, worsening pain, dizziness, syncope
• No sexual intercourse for 14–21 days (until hCG undetectable) — intercourse can trigger rupture
• Avoid NSAIDs (interfere with MTX clearance — use acetaminophen instead) in some protocols; check institutional guidelines
• Avoid folic acid supplements (antagonizes MTX)
• Serial hCG monitoring until undetectable
• No pregnancy for 3 months after MTX (teratogenic effect)

C. Surgical Management — Laparoscopic Options

"Salpingostomy is preferred to salpingectomy if the patient is stable and the procedure is technically feasible." — Rosen's Emergency Medicine

"An increasing number of surgeries are being performed through the laparoscope. The advent of transvaginal ultrasonography has resulted in earlier diagnosis and a trend toward nonoperative management."

---

SPECIAL TYPES OF ECTOPIC PREGNANCY

Interstitial (Cornual) Ectopic

• Implants within the intramural portion of the tube as it traverses the uterine myometrium
• Rich blood supply → can grow larger before rupturing (may not rupture until 9–16 weeks)
• Higher mortality than standard tubal ectopic — rupture causes massive hemorrhage
• Diagnosis: TVS shows empty uterine cavity + gestational sac lateral to uterine cavity with thin (<5 mm) myometrial mantle surrounding it
• Treatment: MTX (if unruptured, early) or cornual resection/hysterectomy

Cervical Ectopic

• <1% of ectopics; predisposing factors: prior D&C, Asherman syndrome, prior cervical surgery
• Presents with painless heavy vaginal bleeding (mimics placenta previa)
• Diagnosis: gestational sac within the cervical canal on TVS
• Treatment: MTX (preferred if viable); if uncontrolled bleeding → cervical sutures, Foley balloon tamponade, UAE, hysterectomy as last resort

Ovarian Ectopic

• 0.5% of ectopics; difficult to distinguish from corpus luteum cyst clinically
• Criteria (Spiegelberg): tube intact on same side, sac in position of ovary, connected to uterus by ovarian ligament, ovarian tissue in sac wall

Abdominal Ectopic

• ~1%; usually from early tubal rupture/abortion with reimplantation on peritoneum, bowel, omentum, or mesentry
• Can occasionally reach viability (advanced abdominal pregnancy)
• High maternal (and fetal) morbidity; requires surgical management

Cesarean Scar Ectopic

• Implantation at prior uterine incision scar
• Increasingly common with rising cesarean rates
• Risk of massive hemorrhage and uterine rupture
• Diagnosis: empty uterine cavity, empty cervical canal, gestational sac at anterior uterine isthmus within the scar
• Treatment: MTX, UAE, surgical resection, or hysterectomy depending on clinical status

Heterotopic Pregnancy

• Simultaneous IUP + ectopic in the same patient
• Spontaneous rate: ~1/3,000; with IVF: up to 1%
• Risk factors: ART, multiple embryo transfer, PID history, tubal surgery
• Presentation: pain + bleeding with known IUP → do not be falsely reassured by the IUP
• Diagnosed in first 5–8 weeks; only 26% diagnosable by TVS (rest require laparoscopy)
• Treatment: surgical or US-guided injection of KCl into the ectopic pregnancy (to preserve the IUP); overall delivery rate for the IUP after treatment ~70%
• MTX is contraindicated (would harm the IUP)

---

DIFFERENTIAL DIAGNOSIS

---

FOLLOW-UP AFTER TREATMENT

After MTX:

• Weekly hCG until undetectable
• No pregnancy for 3 months (MTX teratogenic)
• Monitor for signs of treatment failure (pain, instability) — can rupture even during MTX therapy
• Persistent ectopic (hCG not falling adequately): repeat MTX dose or surgery

After Surgical Treatment:

• hCG to zero post-salpingostomy (to exclude persistent ectopic)
• Not needed after salpingectomy (unless concern for residual tissue)
• Discuss future fertility counseling
• Risk of recurrent ectopic in future pregnancies: up to 22%

---

RECURRENCE AND FUTURE FERTILITY

---

KEY CLINICAL PEARLS

1. Any woman of reproductive age + pain or bleeding = pregnancy test first, always
2. The classic triad is present in a minority — do not wait for it
3. Risk factors absent in ~50% of patients — do not use their absence to downgrade concern
4. A single hCG level cannot exclude ectopic — even <500 mIU/mL ectopics have ruptured
5. Vital signs can be normal despite significant hemoperitoneum — bradycardia can occur paradoxically
6. An IUP on US does not exclude ectopic in IVF patients — heterotopic always possible
7. Indeterminate US + hCG > discriminatory zone → high suspicion; manage as ectopic until proven otherwise
8. MTX: use when stable, unruptured, <4 cm, no cardiac activity, hCG <5,000 ideally
9. "Separation pain" 3–7 days after MTX is expected — distinguish from rupture by US + vitals
10. After treatment: no pregnancy for 3 months (MTX); watch for recurrence

---

---

Source note: Williams Obstetrics is not in this library. Content is from Berek & Novak's Gynecology (primary — the most comprehensive GTD reference available), Creasy & Resnik's Maternal-Fetal Medicine, Rosen's Emergency Medicine, Robbins & Cotran Pathologic Basis of Disease, and Textbook of Family Medicine 9e.

---

Molar Pregnancy (Gestational Trophoblastic Disease) — Complete Detailed Reference

---

OVERVIEW — The GTD Spectrum

"GTD is the most successfully treated gynecologic cancer and one of the most curable solid tumors in women." — Creasy & Resnik's Maternal-Fetal Medicine

Full GTD Classification

"GTNs are among the rare human tumors that can be cured even in the presence of widespread dissemination." — Berek & Novak's Gynecology

---

INCIDENCE AND EPIDEMIOLOGY

• Socioeconomic and nutritional factors — decreasing dietary carotene (Vitamin A precursor) and animal fat associated with increased complete mole rate
• South Korea's declining incidence attributed to Westernized diet and improved living standards

---

TYPE 1: COMPLETE HYDATIDIFORM MOLE

Pathogenesis / Cytogenetics

"Complete moles arise from an ovum fertilized by a haploid sperm, which duplicates its own chromosomes. The ovum nucleus may be absent or inactivated." — Berek & Novak's Gynecology

Gross and Microscopic Pathology

• Gross: delicate, friable mass of thin-walled, translucent, cystic, grape-like vesicles — swollen edematous (hydropic) villi
• Microscopic:
  • All villi are enlarged, smooth, oval with central cavitation (cisterns)
  • Diffuse trophoblastic hyperplasia (both cyto- and syncytiotrophoblast)
  • No scalloping of villi
  • No trophoblastic stromal inclusions
  • No fetal tissue

Risk Factors Specific to Complete Mole

• Age >40 years: 2–10 fold increased risk
• Age >50 years: 1 in 3 pregnancies is molar
• Adolescents: 7-fold increased risk
• Prior molar pregnancy: significantly increased recurrence
• Prior miscarriage
• Low dietary carotene / animal fat intake
• Extremes of reproductive age (both ends of the spectrum)

---

TYPE 2: PARTIAL (INCOMPLETE) HYDATIDIFORM MOLE

Pathogenesis / Cytogenetics

Microscopic Pathology

• Focal (not diffuse) hydropic villi
• Focal trophoblastic hyperplasia
• Scalloping of chorionic villi present (characteristic)
• Trophoblastic stromal inclusions present
• Fetal/embryonic tissue present (often with anomalies)

---

COMPLETE vs. PARTIAL MOLE — Comparison Table

---

CLINICAL FEATURES

Complete Mole — Classic Presentation (Historic vs. Current)

Note: With widespread early TVS use, many complete moles are now diagnosed at 9–10 weeks with fewer classic features.

Vaginal Bleeding

• Most common presenting symptom
• Molar tissues separate from decidua → disrupting maternal vessels
• Large volumes of retained blood may distend endometrial cavity
• May be considerable and prolonged

Excessive Uterine Size

• Present in ~28% currently
• Due to: chorionic tissue bulk + retained blood + trophoblastic overgrowth
• Associated with markedly elevated hCG

Theca Lutein Ovarian Cysts

• Present in ~50% of complete moles
• Result from ovarian hyperstimulation by very high hCG levels
• Can be large (up to 30 cm); may not be palpable (uterus enlarged) — US documents them
• Spontaneously regress within 2–4 months after evacuation
• Complications: torsion, rupture → acute pelvic pain → laparoscopy
• Do NOT need to be removed (they regress)

Preeclampsia Before 24 Weeks — Pathognomonic

Preeclampsia developing before 24 weeks should always prompt consideration of molar pregnancy

• Hypertension, proteinuria, hyperreflexia — classic preeclampsia features
• Eclamptic convulsions rare
• Occurs almost exclusively when uterine size is excessive and hCG markedly elevated

Hyperemesis Gravidarum

• From extremely high hCG levels (hCG has TSH-like and FSH-like activity)
• May cause severe electrolyte disturbances requiring IV fluid replacement
• Severe nausea/vomiting disproportionate to gestational age

Hyperthyroidism

• Historically 7%; rare now with early diagnosis
• hCG has TSH-like activity → stimulates thyroid → elevated free T3 and T4
• Symptoms: tachycardia, warm skin, tremor
• CRITICAL: Anesthesia or surgery can precipitate thyroid storm in untreated hyperthyroid patients
• Before molar evacuation: if hyperthyroid → administer β-blockers first; have treatment for thyroid storm ready
• Thyroid storm: hyperthermia, delirium, convulsions, tachycardia, high-output heart failure, cardiovascular collapse

Respiratory Distress (Trophoblastic Pulmonary Embolism)

• Occurs during or after molar evacuation
• Chest pain, dyspnea, tachypnea, tachycardia, bilateral pulmonary infiltrates on CXR
• From: trophoblastic cell embolization, cardiopulmonary effects of thyroid storm, preeclampsia, massive fluid replacement
• Usually resolves within 72 hours with cardiopulmonary support
• May require mechanical ventilation

Partial Mole — Clinical Presentation

• Usually no dramatic features of complete mole
• Presents like incomplete or missed abortion — diagnosed on histology of curettage specimen
• Main symptom: vaginal bleeding (73%)
• Excessive uterine size: ~4%
• Preeclampsia: ~2.5%
• No theca lutein cysts, no hyperemesis, no hyperthyroidism typically
• Pre-evacuation hCG >100,000 mIU/mL in only 7% of partial moles (vs. common in complete)
• 91% initially diagnosed as incomplete/missed abortion — only confirmed as partial mole on pathologic review

---

DIAGNOSIS

Ultrasound — Classic Features

Note: With early diagnosis (9 weeks), the snowstorm pattern may not yet be fully developed. Many early complete moles appear as a heterogeneous echogenic mass without discrete cysts.

Quantitative β-hCG

• Markedly elevated — often >100,000 mIU/mL in complete mole
• In partial mole: usually lower; >100,000 mIU/mL in only ~7%
• hCG is the essential tumor marker for diagnosis, treatment monitoring, and surveillance

Histopathology — Definitive Diagnosis

• All products of conception from D&C should be sent for pathologic examination
• Confirms mole type and rules out choriocarcinoma
• Partial moles are frequently only diagnosed on histology (not clinically suspected)

"Phantom hCG" / False-Positive hCG

• Heterophilic antibodies in serum can create false-positive serum hCG results
• Leads to inappropriate treatment for GTN
• Exclusion: run simultaneous urine hCG — serum heterophilic antibodies NOT excreted in urine → urine hCG will be negative in phantom hCG
• Alternative: serial dilution of serum (true hCG shows linear decrease); or use alternative hCG assay platform

---

MANAGEMENT

Step 1: Pre-Evacuation Workup

• Baseline quantitative serum hCG
• CBC, blood type and screen, coagulation studies
• Thyroid function tests (T3, T4, TSH) — check for hyperthyroidism
• Chest X-ray (rule out pulmonary metastases)
• Renal and liver function tests
• Pelvic ultrasound (document mole + theca lutein cysts)
• Two large-bore IV lines
• If hyperthyroid → consult endocrinology + anesthesia; administer β-blockers before proceeding

Step 2: Uterine Evacuation

1. Oxytocin infusion started before anesthesia induction (reduces bleeding risk)
2. Cervical dilation — bleeding often increases at this stage (expected); retained blood expelled
3. Suction curettage — use 12-mm cannula; uterine size decreases dramatically within minutes; bleeding controlled
   • If uterus >14 weeks: place one hand on fundus, massage uterus during evacuation (prevents perforation)
4. Sharp curettage — gentle, after suction complete, to remove residual molar tissue
5. Oxytocin continued after evacuation to maintain uterine tone
6. Rh immune globulin — trophoblast cells express RhD antigen → administer if Rh-negative
7. Ultrasound guidance preferred during evacuation

• Risk of incomplete evacuation (up to 25%)
• Hemorrhage
• Infection
• Trophoblastic embolization → respiratory failure, death
• Higher risk of needing subsequent chemotherapy

• Patient desires sterilization
• Ovaries preserved even with theca lutein cysts present (cysts will regress)
• Does NOT prevent metastasis — hCG monitoring still required post-hysterectomy

Step 3: Prophylactic Chemotherapy (Controversial)

---

POST-EVACUATION SURVEILLANCE — hCG Monitoring

Complete Mole Protocol

Partial Mole Protocol

• Weekly hCG until undetectable → then 3 months monitoring (shorter than complete mole)
• Risk of GTN after partial mole is very low (1–5%)
• Surveillance may be safely abbreviated once hCG is undetectable

Diagnosis of Post-Molar GTN (Referral Criteria)

• hCG plateaus (no change) over 3 weekly measurements
• hCG rises on 2 consecutive weekly measurements
• hCG persists for more than 6 months without becoming undetectable

Contraception During Surveillance

• Highly recommended during entire hCG surveillance period — pregnancy would interfere with hCG monitoring
• Oral contraceptives: safe to use after molar evacuation (prospective trials confirm no increased GTN risk)
• IUD: avoid until hCG is normal (risk of uterine perforation, bleeding, infection with elevated hCG)
• Barrier methods: acceptable

When Can Patient Try to Conceive?

• After complete mole: avoid pregnancy for 12 months (1 year) from hCG remission
• After partial mole: avoid pregnancy for at least 6 months after hCG remission
• After GTN/chemotherapy: wait until 12 months after completion of chemotherapy — subsequent pregnancies have normal outcomes with no increased congenital abnormality risk

---

HIGH-RISK MARKERS — Who is at Risk for Developing GTN?

---

GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)

Nonmetastatic (Invasive Mole) — 15% after complete mole evacuation

• Irregular vaginal bleeding
• Persistent/rising hCG
• Uterine subinvolution or asymmetric enlargement
• Theca lutein cysts persist
• Tumor may perforate myometrium → hemoperitoneum
• Erosion into uterine vessels → vaginal hemorrhage
• Sepsis if necrotic tumor infected → purulent discharge, pelvic pain

Metastatic GTN — 4% after complete mole; more common after nonmolar pregnancies

Choriocarcinoma

• Highly invasive, frequently metastatic
• No chorionic villi histologically — sheets of anaplastic syncytiotrophoblast and cytotrophoblast
• Can follow any gestational event: molar pregnancy, spontaneous abortion, ectopic pregnancy, or term delivery
• After nonmolar pregnancies → always choriocarcinoma histologically
• Highly responsive to chemotherapy (unlike PSTT/ETT)
• Curable even with widespread metastases

FIGO Staging

Prognostic Scoring System

• Low-risk (score 0–6): single-agent chemotherapy (MTX or actinomycin D); cure rate ~100%
• High-risk (score ≥7): combination chemotherapy (EMA-CO: etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine); cure rate ~90–95%

Placental Site Trophoblastic Tumor (PSTT) and Epithelioid Trophoblastic Tumor (ETT)

• Rare; composed of intermediate trophoblasts
• Produce small amounts of hCG and human placental lactogen (hPL)
• Tend to remain confined to uterus initially; metastasize late
• Relatively insensitive to chemotherapy — surgery (hysterectomy) is treatment of choice
• PSTT and ETT are the only GTD forms where hPL measurement (not hCG) is the primary marker

---

MOLAR PREGNANCY COEXISTING WITH NORMAL FETUS (Twin Molar Pregnancy)

• Occurs in 1 of 20,000–100,000 pregnancies
• One twin = complete mole; other = normal diploid fetus
• Associated complications: fetal death, hemorrhage, preeclampsia, persistent GTN after evacuation
• 60% who continue pregnancy experience spontaneous abortion or fetal demise before 24 weeks
• 40% deliver a live infant (most after 32 weeks)
• Rate of persistent GTN requiring chemotherapy: no different from singleton mole — not increased by continuing pregnancy
• Management: multidisciplinary (MFM + gynecologic oncology)

---

SUBSEQUENT PREGNANCIES AFTER GTD

---

SUMMARY TABLE

---

KEY CLINICAL PEARLS

1. Preeclampsia before 24 weeks = molar pregnancy until proven otherwise
2. Hyperemesis out of proportion to gestational age → check hCG, do ultrasound for mole
3. Partial moles are almost always misdiagnosed clinically as miscarriage — only confirmed on histology → send all POC specimens for pathology
4. Do NOT use misoprostol alone for molar evacuation — risk of trophoblastic embolism and respiratory failure
5. Treat hyperthyroidism before evacuation — anesthesia can trigger thyroid storm
6. Theca lutein cysts do NOT need surgical removal — they regress within 2–4 months after hCG normalization
7. hCG is the perfect tumor marker — use it for diagnosis, treatment monitoring, and recurrence detection
8. Once hCG becomes undetectable after evacuation → risk of GTN approaches zero
9. Phantom hCG: if hCG elevated but no pregnancy visible → run urine hCG to exclude false positive
10. After GTN treated with chemotherapy → normal future pregnancies are expected — do not deny fertility

---

---

Obstetrics Question Bank

All Topics — MCQ with Answers and Explanations

---

SECTION 1: OBSTETRIC ANATOMY & LABOR

---

• A) Station −2
• B) Station +1
• C) Station 0
• D) Station −1

---

• A) First stage: full dilation to delivery of baby
• B) Second stage: onset of contractions to full cervical dilation
• C) Third stage: delivery of baby to delivery of placenta
• D) Fourth stage: from onset of contractions to full dilation

• 1st stage: onset of contractions → full dilation (10 cm)
• 2nd stage: full dilation → delivery of baby
• 3rd stage: delivery of baby → delivery of placenta

---

• A) Immediate cesarean section is indicated
• B) This is within normal limits for a nullipara
• C) The latent phase is considered prolonged; conservative management is appropriate
• D) Amniotomy should be performed immediately

---

• A) 3 cm cervical dilation
• B) 4 cm cervical dilation
• C) 6 cm cervical dilation
• D) 8 cm cervical dilation

---

• A) Android
• B) Anthropoid
• C) Platypelloid
• D) Gynecoid

---

• A) Gush of blood
• B) Cord lengthening
• C) Uterus becomes globular and firm
• D) Fetal heart rate returns to baseline

---

• A) Postdates pregnancy
• B) Prior low transverse cesarean section
• C) Multiparity
• D) PROM at term

---

• A) The same duration
• B) More than 2 hours longer
• C) Shorter due to increased uterine tone
• D) 30 minutes longer

---

SECTION 2: ECTOPIC PREGNANCY

---

• A) First trimester
• B) Second trimester
• C) Third trimester
• D) Equal across all trimesters

---

• A) Diagnose ectopic pregnancy and administer methotrexate immediately
• B) Perform emergency laparoscopy
• C) Repeat hCG in 48 hours and repeat TVS when hCG rises above discriminatory zone
• D) Perform D&C immediately

---

• A) 500–800 mIU/mL
• B) 1,500–2,000 mIU/mL
• C) 5,000–6,000 mIU/mL
• D) 10,000–15,000 mIU/mL

---

• A) Normal viable intrauterine pregnancy
• B) Abnormal pregnancy — ectopic or failing IUP
• C) Normal variation within range
• D) Rapidly growing molar pregnancy

---

• A) Ectopic pregnancy
• B) Failing IUP
• C) Normal viable IUP
• D) Molar pregnancy

---

• A) hCG level of 3,000 mIU/mL
• B) Ectopic mass of 3.2 cm
• C) Breastfeeding
• D) No cardiac activity detected

---

• A) Treatment failure with impending rupture
• B) "Separation pain" — expected effect of MTX
• C) Allergic reaction to MTX
• D) Ovarian torsion

---

• A) Ampullary
• B) Fimbrial
• C) Isthmic
• D) Interstitial (cornual)

---

• A) Adnexal mass without intrauterine pregnancy
• B) Moderate free fluid in cul-de-sac
• C) Empty uterus with hCG above discriminatory zone
• D) Cardiac activity detected in the fallopian tube

---

• A) 1 in 30,000
• B) 1 in 4,000
• C) 1 in 100
• D) 1 in 500

---

SECTION 3: MOLAR PREGNANCY & GTD

---

• A) 69,XXY (triploid)
• B) 46,XX (all maternal)
• C) 46,XX (all paternal — androgenetic)
• D) 45,X (monosomy)

---

• A) 46,XX all paternal
• B) 69,XXX or 69,XXY (triploid)
• C) 45,X (monosomy)
• D) 46,XY normal

---

• A) Placenta previa
• B) Complete hydatidiform mole
• C) Placental abruption
• D) Threatened miscarriage

---

• A) Uterine rupture
• B) Cervical stenosis
• C) Persistent/rising serum hCG indicating GTN
• D) Ovarian failure from theca lutein cysts

---

• A) 15–20%
• B) 2.5%
• C) 10%
• D) 0.5%

---

• A) 3 months
• B) 6 months
• C) 12 months (1 year)
• D) 2 years

---

• A) Uterine size equal to dates
• B) hCG of 50,000 mIU/mL
• C) hCG >100,000 mIU/mL + uterine size > dates + theca lutein cysts ≥6 cm
• D) Age under 30

---

• A) Insufficient cervical ripening
• B) Risk of incomplete evacuation, hemorrhage, infection, and trophoblastic pulmonary embolism
• C) It is too expensive
• D) It does not work before 12 weeks

---

• A) Administer misoprostol for cervical ripening
• B) Administer β-adrenergic blocking agents to prevent thyroid storm
• C) Give IV methotrexate
• D) Place cervical cerclage

---

SECTION 4: MISCARRIAGE (SPONTANEOUS ABORTION)

---

• A) Inevitable abortion
• B) Threatened abortion
• C) Missed abortion
• D) Incomplete abortion

---

• A) Uterine septum
• B) Antiphospholipid syndrome
• C) Chromosomal abnormalities
• D) Luteal phase defect

---

• A) Threatened miscarriage
• B) Nonviable (embryonic demise / missed abortion)
• C) Normal — cardiac activity not expected until 10 weeks
• D) Partial molar pregnancy

---

• A) Chromosomal aneuploidy
• B) Antiphospholipid syndrome (APS)
• C) Uterine septum
• D) Advanced maternal age

---

• A) Missed abortion
• B) Incomplete abortion
• C) Inevitable abortion
• D) Threatened abortion

---

• A) 25 µg orally
• B) 200 µg orally
• C) 800 µg vaginally
• D) 400 µg sublingually only

---

SECTION 5: PLACENTAL ABRUPTION

---

• A) Painless bright red bleeding
• B) Sudden fetal tachycardia with no bleeding
• C) Painful dark vaginal bleeding
• D) Rupture of membranes with bloody fluid

---

• A) 1–2%
• B) 5%
• C) 10–20% (concealed hemorrhage)
• D) 50%

---

• A) Maternal hypertension
• B) Cocaine use
• C) Prior placental abruption
• D) Cigarette smoking

---

• A) Platelet count
• B) Prothrombin time
• C) Fibrin degradation products (FDP)
• D) Hemoglobin level

---

• A) Immediate cesarean delivery
• B) Expectant management with betamethasone, close monitoring
• C) Induction of labor with oxytocin
• D) Tocolysis with magnesium and discharge home

---

• A) Immediately after examination
• B) After 2 hours of monitoring
• C) After 6 hours of continuous CTG monitoring if reassuring
• D) After 24 hours regardless of symptoms

---

• A) Placenta completely covering the cervical os
• B) Uterus infiltrated with blood penetrating through the myometrium to the peritoneum
• C) Uterine rupture from prior cesarean scar
• D) Abnormal placental attachment to the myometrium

---

• A) 150–250 mg/dL
• B) 200–300 mg/dL
• C) 400–650 mg/dL
• D) 100–150 mg/dL

---

SECTION 6: PLACENTA PREVIA

---

• A) Allow the examination — it is safe
• B) Perform a speculum examination first to identify source of bleeding
• C) Immediately perform digital exam to assess dilation
• D) Stop — do NOT perform digital examination until placenta previa is excluded by ultrasound

---

• A) She will definitely need a cesarean delivery
• B) She has placenta previa and needs immediate hospitalization
• C) 90% of 2nd trimester previas resolve by term — follow-up US at 32 weeks
• D) She needs cervical cerclage placement immediately

---

• A) Full bladder prevents adequate TVS imaging
• B) Full bladder pushes uterine walls together, creating a false-positive previa diagnosis
• C) Full bladder prevents the probe from being inserted
• D) Full bladder increases the risk of hemorrhage

---

• A) Allow labor to begin spontaneously
• B) Cesarean delivery now — do not delay
• C) Elective cesarean at or just after 36 weeks gestation
• D) Await spontaneous labor at 40 weeks

---

• A) Uterine rupture
• B) Postpartum hemorrhage from LUS atony
• C) Cervical laceration
• D) Placenta accreta

---

• A) It is associated with fundal placental implantation
• B) Fetal survival is 97% with antenatal diagnosis vs. 44% without
• C) Management is expectant until term
• D) The vessels are protected by Wharton's jelly

---

SECTION 7: PLACENTA ACCRETA SPECTRUM (PAS)

---

• A) 3%
• B) 11%
• C) 40%
• D) 61%

---

• A) Wharton's jelly
• B) Nitabuch fibrinoid layer (decidua basalis)
• C) Chorion laeve
• D) Amnion

---

• A) Placenta completely covering the os
• B) Loss of retroplacental hypoechoic zone + placental lacunae ("Swiss cheese" appearance)
• C) Posterior placenta with normal clear zone
• D) Theca lutein cysts

---

• A) 28–30 weeks
• B) 34–35 weeks after corticosteroids
• C) 38–40 weeks
• D) 32 weeks

---

• A) Manual placental removal at cesarean
• B) Misoprostol + oxytocin to facilitate placental separation
• C) Planned cesarean hysterectomy with placenta left in situ
• D) Uterine artery embolization alone

---

• A) MTX is highly effective for PAS and should be used routinely
• B) MTX is unequivocally NOT recommended — no proven efficacy and one death reported from complications
• C) MTX should be given prophylactically after every cesarean
• D) MTX replaces the need for serial hCG monitoring

---

SECTION 8: HYPERTENSIVE DISORDERS OF PREGNANCY

---

• A) BP ≥140/90 after 20 weeks with no proteinuria
• B) BP ≥140/90 after 20 weeks + proteinuria >300 mg/24 hr (or PCR ≥0.3)
• C) BP ≥160/110 at any time in pregnancy
• D) Chronic HTN diagnosed before pregnancy

---

• A) BP of 138/88 mmHg
• B) Proteinuria of 250 mg/24 hours
• C) Platelet count of 85,000/µL
• D) Creatinine of 0.9 mg/dL

---

• A) Expectant management until 40 weeks
• B) Deliver within 24 hours + IV magnesium sulfate
• C) Start antihypertensives and monitor weekly
• D) Immediate cesarean only

---

• A) 2 g IV over 30 minutes
• B) 4–6 g IV over 15–20 minutes, then 2 g/hr maintenance
• C) 10 g IM
• D) 1 g/hr from the start

---

• A) Respiratory depression
• B) Cardiac arrest
• C) Loss of deep tendon reflexes (DTRs)
• D) Urine output decreasing

---

• A) Naloxone 0.4 mg IV
• B) Calcium gluconate 1 g IV
• C) Furosemide 40 mg IV
• D) Flumazenil

---

• A) Hypertension + edema + leukocytosis
• B) Hemolysis + elevated liver enzymes + low platelets
• C) Hypotension + elevated LFTs + high platelets
• D) Hematuria + elevated creatinine + low BP

---

• A) Hypertension >160/110 in pregnancy
• B) Preeclampsia + new-onset grand mal seizures not attributable to other causes
• C) HELLP syndrome with severe hypertension
• D) Hypertensive emergency in the 1st trimester

---

• A) Labetalol and methyldopa
• B) Nifedipine and hydralazine
• C) ACE inhibitors and ARBs
• D) Beta-blockers and calcium channel blockers

---

• A) Furosemide IV
• B) IV labetalol or IV hydralazine
• C) IV enalapril
• D) Oral amlodipine

---

• A) Lisinopril
• B) Valsartan
• C) α-methyldopa (Aldomet) or labetalol
• D) Atenolol

---

SECTION 9: MIXED / INTEGRATED QUESTIONS

---

• A) Perform digital cervical examination
• B) Obtain IV access, continuous CTG, and perform transabdominal US — DO NOT perform digital exam
• C) Immediate cesarean delivery
• D) Perform amniotomy

---

• A) Complete molar pregnancy
• B) Multiple gestation
• C) Placenta accreta
• D) Antiphospholipid syndrome

---

• A) Uterine rupture
• B) Placenta previa alone
• C) Placenta accreta spectrum
• D) Postpartum hemorrhage from uterine atony

---

• A) Abruption → painless bright red bleeding
• B) Previa → painful dark bleeding + rigid uterus
• C) Abruption → painful dark bleeding + hypertonic uterus
• D) Vasa previa → maternal hemorrhage without fetal distress

• Abruption: painful, dark blood, hypertonic/tender uterus
• Previa: painless, bright red, soft uterus
• Vasa previa: fetal hemorrhage (fetal blood vessels) → fetal distress + bleeding when membranes rupture

---

• A) Placenta accreta
• B) Complete hydatidiform mole
• C) Placental abruption
• D) Dichorionic twin pregnancy

---

• A) Rh-negative patient with placenta previa and heavy bleeding who has NOT yet received her 28-week dose
• B) Rh-positive patient with placental abruption
• C) Rh-negative patient who received their 28-week prophylaxis and now has threatened miscarriage
• D) All pregnant patients regardless of Rh status

---

SCORING GUIDE

---

---

The Earliest Cardinal Movement of Labor — ENGAGEMENT

---

The Cardinal Movements — Full Sequence

---

ENGAGEMENT — Why It Is the Earliest and What It Means

Definition

"Engagement is defined by descent of the biparietal diameter of the fetus to a level below the maternal pelvic inlet." — Pfenninger and Fowler's Procedures for Primary Care

Clinical Recognition

• Clinically suggested when the lowest portion of the occiput (not caput succedaneum) is at or below the level of the ischial spines = Station 0
• On abdominal palpation: the head is no longer ballottable / freely mobile; it is "fixed" in the pelvis — only 2/5 or less of the head is palpable abdominally
• The fundal height drops ("lightening") — the mother notices she can breathe more easily but has increased pelvic pressure

Why Engagement Occurs FIRST — The Anatomic Reason

• The transverse diameter is the widest dimension of the inlet
• The anteroposterior (AP) / obstetric conjugate is the narrowest dimension of the inlet (~10–11 cm)
• Therefore, the fetal head must enter the inlet in the transverse (or oblique) diameter — biparietal diameter aligning with the widest transverse dimension
• The biparietal diameter (BPD ≈9.5 cm) must fit through the obstetric conjugate (≥10 cm)

"In most cases, the anteroposterior diameter of the pelvic inlet is the smallest dimension. Thus, the smallest diameter of the fetal head (biparietal diameter) must align with the anteroposterior diameter of the pelvic inlet." — Pfenninger and Fowler's Procedures for Primary Care

• No engagement → no labor progress
• Engagement confirms that the pelvic inlet is adequate to allow fetal descent
• It is the gatekeeper — the head must first pass the narrowest dimension at the inlet before all subsequent movements occur

---

When Does Engagement Occur?

"Often occurs before the onset of labor, especially in nulliparas." — Pfenninger and Fowler's Procedures for Primary Care

• In a nullipara at 38 weeks with a non-engaged head → consider pelvic inadequacy (android pelvis, cephalopelvic disproportion)
• In a multipara → non-engagement before labor is normal and not concerning

---

What Happens to the Head at Engagement — The Position

• Left occipitotransverse (LOT) — most common (~40%)
• Left occipitoanterior (LOA) — second most common
• Right occipitotransverse (ROT), Right occipitoanterior (ROA) — less common
• Occipitoposterior (OP) — ~5–10% — less favorable, often results in longer, more painful labor

---

Clinical Significance of Non-Engagement

---

Why the Sequence Proceeds in This Order — Summary

"As the fetal head continues to descend, the biparietal diameter of the fetus rotates to align with the lateral diameter (intertuberous diameter) of the maternal pelvic outlet." — Pfenninger and Fowler's Procedures for Primary Care

1. It is the entry of the presenting part into the pelvis — before this, the fetus is entirely above the pelvis
2. Without clearing the inlet, no subsequent movement is anatomically possible
3. It confirms pelvic adequacy at the inlet level — a critical obstetric gate

---

Summary Answer

---